Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment.

Xu Y, Sun Y, Yao L, Shi L, Wu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, He L, Li P, Xie Y.

Ann Oncol. 2008 Aug;19(8):1423-9. doi: 10.1093/annonc/mdn155. Epub 2008 Apr 11.

PMID:
18407954
2.

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.

Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G; Breast International Group (BIG) 1-98 Collaborative Group.

J Natl Cancer Inst. 2012 Mar 21;104(6):441-51. doi: 10.1093/jnci/djs125. Epub 2012 Mar 6.

3.

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

Punglia RS, Burstein HJ, Winer EP, Weeks JC.

J Natl Cancer Inst. 2008 May 7;100(9):642-8. doi: 10.1093/jnci/djn100. Epub 2008 Apr 29.

4.

No association between CYP2D6*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment.

Toyama T, Yamashita H, Sugiura H, Kondo N, Iwase H, Fujii Y.

Jpn J Clin Oncol. 2009 Oct;39(10):651-6. doi: 10.1093/jjco/hyp076. Epub 2009 Jul 11.

PMID:
19596663
5.

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA.

J Natl Cancer Inst. 2005 Jan 5;97(1):30-9.

PMID:
15632378
6.

Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy.

Kiyotani K, Mushiroda T, Sasa M, Bando Y, Sumitomo I, Hosono N, Kubo M, Nakamura Y, Zembutsu H.

Cancer Sci. 2008 May;99(5):995-9. doi: 10.1111/j.1349-7006.2008.00780.x. Epub 2008 Feb 24.

7.
8.

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.

Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Boländer J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H.

JAMA. 2009 Oct 7;302(13):1429-36. doi: 10.1001/jama.2009.1420.

9.

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.

Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN.

Breast Cancer Res Treat. 2007 Jan;101(1):113-21. Epub 2006 Nov 18.

PMID:
17115111
10.

Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.

Park IH, Ro J, Park S, Lim HS, Lee KS, Kang HS, Jung SY, Lee S.

Breast Cancer Res Treat. 2012 Jan;131(2):455-61. doi: 10.1007/s10549-011-1425-2. Epub 2011 Mar 25.

PMID:
21437611
11.

Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.

Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, Kisanga ER, Mellgren G, Steen VM, Lien EA.

Ann Oncol. 2008 Jan;19(1):56-61. Epub 2007 Oct 18.

PMID:
17947222
12.

The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.

Bijl MJ, van Schaik RH, Lammers LA, Hofman A, Vulto AG, van Gelder T, Stricker BH, Visser LE.

Breast Cancer Res Treat. 2009 Nov;118(1):125-30. doi: 10.1007/s10549-008-0272-2. Epub 2009 Feb 3.

PMID:
19189212
13.

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.

Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN.

J Clin Oncol. 2005 Dec 20;23(36):9312-8.

PMID:
16361630
14.

Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment.

Stingl JC, Parmar S, Huber-Wechselberger A, Kainz A, Renner W, Seeringer A, Brockmöller J, Langsenlehner U, Krippl P, Haschke-Becher E.

Curr Med Res Opin. 2010 Nov;26(11):2535-42. doi: 10.1185/03007995.2010.518304. Epub 2010 Sep 17.

PMID:
20849243
15.

Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients.

Kiyotani K, Mushiroda T, Imamura CK, Tanigawara Y, Hosono N, Kubo M, Sasa M, Nakamura Y, Zembutsu H.

Breast Cancer Res Treat. 2012 Jan;131(1):137-45. doi: 10.1007/s10549-011-1777-7. Epub 2011 Sep 23.

PMID:
21947681
16.

Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.

Gaston C, Kolesar J.

Clin Adv Hematol Oncol. 2008 Nov;6(11):825-33.

PMID:
19194367
17.

Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.

Goetz MP, Suman VJ, Couch FJ, Ames MM, Rae JM, Erlander MG, Ma XJ, Sgroi DC, Reynolds CA, Lingle WL, Weinshilboum RM, Flockhart DA, Desta Z, Perez EA, Ingle JN.

Clin Cancer Res. 2008 Sep 15;14(18):5864-8. doi: 10.1158/1078-0432.CCR-08-0619.

18.

CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.

Abraham JE, Maranian MJ, Driver KE, Platte R, Kalmyrzaev B, Baynes C, Luccarini C, Shah M, Ingle S, Greenberg D, Earl HM, Dunning AM, Pharoah PD, Caldas C.

Breast Cancer Res. 2010;12(4):R64. doi: 10.1186/bcr2629. Epub 2010 Aug 23.

19.

CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis.

Zeng Z, Liu Y, Liu Z, You J, Chen Z, Wang J, Peng Q, Xie L, Li R, Li S, Qin X.

Cancer Chemother Pharmacol. 2013 Aug;72(2):287-303. doi: 10.1007/s00280-013-2195-9. Epub 2013 May 28. Review.

PMID:
23712329
20.

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.

Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, Hillman G, Hayes DF, Stearns V, Flockhart DA.

Clin Pharmacol Ther. 2006 Jul;80(1):61-74.

Supplemental Content

Support Center